EP3294273A4 - Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device - Google Patents
Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device Download PDFInfo
- Publication number
- EP3294273A4 EP3294273A4 EP16793347.2A EP16793347A EP3294273A4 EP 3294273 A4 EP3294273 A4 EP 3294273A4 EP 16793347 A EP16793347 A EP 16793347A EP 3294273 A4 EP3294273 A4 EP 3294273A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- lumen
- intestinal tract
- antibody preparations
- delivery device
- swallowable drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Materials For Medical Uses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562159134P | 2015-05-08 | 2015-05-08 | |
PCT/US2016/031548 WO2016183040A1 (en) | 2015-05-08 | 2016-05-09 | Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3294273A1 EP3294273A1 (en) | 2018-03-21 |
EP3294273A4 true EP3294273A4 (en) | 2018-12-05 |
Family
ID=57248408
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP16793347.2A Pending EP3294273A4 (en) | 2015-05-08 | 2016-05-09 | Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP3294273A4 (en) |
JP (2) | JP7185401B2 (en) |
CN (1) | CN107835682A (en) |
AU (2) | AU2016261599B2 (en) |
CA (1) | CA2984422C (en) |
WO (1) | WO2016183040A1 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11548940B2 (en) | 2014-05-15 | 2023-01-10 | Rani Therapeutics, Llc | Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US10689460B2 (en) | 2014-05-15 | 2020-06-23 | Incube Labs, Llc | PCSK9 antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
JP2017521479A (en) | 2014-05-15 | 2017-08-03 | ラニ セラピューティクス, エルエルシー | Solid mass pharmaceutical composition comprising a polypeptide and / or protein and method for producing the same |
EP3347050A4 (en) * | 2015-09-08 | 2019-05-22 | InCube Labs, LLC | Pcsk9 antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
US20200315540A1 (en) * | 2016-12-14 | 2020-10-08 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an il-1 inhibitor |
CA3125348A1 (en) * | 2018-12-31 | 2020-07-09 | Rani Therapeutics, Llc | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008031770A2 (en) * | 2006-09-12 | 2008-03-20 | Cosmo Technologies Ltd | Pharmaceutical compositions for the oral or rectal administration of protein substances |
WO2009063222A2 (en) * | 2007-11-15 | 2009-05-22 | Ucl Business Plc | Solid compositions |
US20120027775A1 (en) * | 2010-08-02 | 2012-02-02 | Advanced Technologies And Regenerative Medicine, Llc | Absorbable peg-based hydrogels |
WO2014066468A1 (en) * | 2012-10-25 | 2014-05-01 | Medimmune, Llc | Stable, low viscosity antibody formulation |
WO2015176031A2 (en) * | 2014-05-15 | 2015-11-19 | Incube Labs, Llc | Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6024767B2 (en) * | 1979-08-24 | 1985-06-14 | 塩野義製薬株式会社 | enteric-coated hard capsules |
WO2006052660A2 (en) * | 2004-11-04 | 2006-05-18 | Childrens Hospital Los Angeles Research Institute | Il-7 receptor blockade to suppress immunity |
EP2515992B1 (en) * | 2009-12-24 | 2018-10-10 | Rani Therapeutics, LLC | Swallowable drug delivery device |
US8721620B2 (en) * | 2009-12-24 | 2014-05-13 | Rani Therapeutics, Llc | Swallowable drug delivery device and methods of drug delivery |
US9149617B2 (en) * | 2010-12-23 | 2015-10-06 | Rani Therapeutics, Llc | Device, system and methods for the oral delivery of therapeutic compounds |
US8980822B2 (en) * | 2010-12-23 | 2015-03-17 | Rani Therapeutics, Llc | Therapeutic agent preparations comprising pramlintide for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
ES2773115T3 (en) * | 2011-06-29 | 2020-07-09 | Rani Therapeutics Llc | Therapeutic agent preparations for administration into the lumen of the intestinal tube using a swallowable drug delivery device |
DK3653223T3 (en) * | 2011-06-29 | 2021-11-15 | Rani Therapeutics Llc | UNIT FOR ORAL DELIVERY OF THERAPEUTIC COMPOUNDS |
US20150064241A1 (en) * | 2013-09-05 | 2015-03-05 | Google Inc. | Delivery of Functionalized Particles |
CA2983337A1 (en) * | 2015-05-01 | 2016-11-10 | Incube Labs, Llc | Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins |
-
2016
- 2016-05-09 AU AU2016261599A patent/AU2016261599B2/en active Active
- 2016-05-09 CA CA2984422A patent/CA2984422C/en active Active
- 2016-05-09 WO PCT/US2016/031548 patent/WO2016183040A1/en unknown
- 2016-05-09 JP JP2017557954A patent/JP7185401B2/en active Active
- 2016-05-09 CN CN201680040187.5A patent/CN107835682A/en active Pending
- 2016-05-09 EP EP16793347.2A patent/EP3294273A4/en active Pending
-
2020
- 2020-11-27 JP JP2020196688A patent/JP7232805B2/en active Active
-
2021
- 2021-11-22 AU AU2021269453A patent/AU2021269453A1/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008031770A2 (en) * | 2006-09-12 | 2008-03-20 | Cosmo Technologies Ltd | Pharmaceutical compositions for the oral or rectal administration of protein substances |
WO2009063222A2 (en) * | 2007-11-15 | 2009-05-22 | Ucl Business Plc | Solid compositions |
US20120027775A1 (en) * | 2010-08-02 | 2012-02-02 | Advanced Technologies And Regenerative Medicine, Llc | Absorbable peg-based hydrogels |
WO2014066468A1 (en) * | 2012-10-25 | 2014-05-01 | Medimmune, Llc | Stable, low viscosity antibody formulation |
WO2015176031A2 (en) * | 2014-05-15 | 2015-11-19 | Incube Labs, Llc | Pharmaceutical compositions and methods for fabrication of solid masses comprising polypeptides and/or proteins |
Non-Patent Citations (1)
Title |
---|
LONNBERG ET AL: "Targeting of interleukin-17 in the treatment of psoriasis", CLINICAL, COSMETIC AND INVESTIGATIONAL DERMATOLOGY, 1 September 2014 (2014-09-01), pages 251, XP055328086, DOI: 10.2147/CCID.S67534 * |
Also Published As
Publication number | Publication date |
---|---|
JP2018520995A (en) | 2018-08-02 |
CA2984422A1 (en) | 2016-11-17 |
CA2984422C (en) | 2023-10-17 |
EP3294273A1 (en) | 2018-03-21 |
JP2021042239A (en) | 2021-03-18 |
JP7232805B2 (en) | 2023-03-03 |
AU2021269453A1 (en) | 2021-12-16 |
AU2016261599B2 (en) | 2021-08-26 |
JP7185401B2 (en) | 2022-12-07 |
WO2016183040A1 (en) | 2016-11-17 |
AU2016261599A1 (en) | 2017-11-23 |
CN107835682A (en) | 2018-03-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP3706720A4 (en) | Clotting factor preparations for delivery into tissue of the intestinal tract using a swallowable drug delivery device | |
EP3316872A4 (en) | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device | |
EP3347050A4 (en) | Pcsk9 antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device | |
EP3294273A4 (en) | Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device | |
EP4003458A4 (en) | Unilateral-driven drug infusion device | |
PT2726091T (en) | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device | |
EP3615113A4 (en) | Medicinal inhaler drive mechanism | |
EP4149587A4 (en) | Unidirectional-driven drug infusion device | |
EP3962516A4 (en) | Clotting factor preparations for delivery into tissue of the intestinal tract using a swallowable drug delivery device | |
EP3437676A4 (en) | Liquid medicine administration device | |
EP3302265A4 (en) | Drug delivery capsule | |
EP3445416A4 (en) | Enteral drug delivery system | |
EP3905999A4 (en) | Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device | |
EP3260148A4 (en) | Liquid drug administration device | |
IL279127A (en) | Delivery devices for administering drugs | |
EP3263155A4 (en) | Drug solution administering device | |
EP3597235A4 (en) | Medicinal liquid administering device | |
EP3900727A4 (en) | Immunity mechanism and therapeutic drug for gastrointestinal diseases | |
EP3846885B8 (en) | Medicament delivery device | |
EP3925643A4 (en) | Liquid medicine administration apparatus | |
EP3801703A4 (en) | Tissue integrated drug delivery system | |
EP3925645A4 (en) | Liquid medicine administration apparatus | |
EP3773362A4 (en) | Medical device delivery | |
EP3351286A4 (en) | Device for administering drug solution | |
EP3258990A4 (en) | Micro infusion device for drug delivery |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20171027 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
A4 | Supplementary search report drawn up and despatched |
Effective date: 20181029 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61F 13/00 20060101ALI20181023BHEP Ipc: A61K 9/20 20060101AFI20181023BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20201202 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: RANI THERAPEUTICS, LLC |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230524 |